Analyst favorites — what the screen found 2026-10-21

Manufacturing dominates this result, accounting for 29 of the 40 companies¹˒² that passed the screen on October 20, 2026. This concentration suggests the current set of analyst favorites is clustered rather than diversified across the market.

The companies identified include a range of market caps, from the larger MakeMyTrip Limited at $4.31B³ and Palvella Therapeutics at $1.80B⁴, to smaller firms like First Watch Restaurant Group ($741.78M⁵), Eupraxia Pharmaceuticals ($506.12M⁶), Ovid Therapeutics ($463.83M⁷), and Immunic ($102.06M⁸). The analyst ratings across the 40 matches are tightly grouped, ranging from 1.0 to 1.18⁹, with a median rating of 1.13¹⁰.

Passing this "Analyst favorites" test simply means a company has a strong-buy-leaning consensus from a crowd of analysts. It does not establish that a stock is worth owning, nor does it provide a verdict on future performance. This screen is a filter based on documented bullish sentiment, not a guarantee of value or a prediction of returns. It identifies where analyst consensus currently sits, but it does not account for the risks that a broad consensus may overlook.